Payment overview · 2025
General Payments
$3,069.94
65 reported records · 11 companies
Healthcare provider profile · identity verified
Mingzhu Xu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1285864983
Verified facts
What the public records show
CMS Open Payments records show Mingzhu Xu, MD received $3,069.94 in general payments during 2025 across 65 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $710.88 | 23.2% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $618.10 | 20.1% | 16 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $592.16 | 19.3% | 13 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $193.92 | 6.3% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $193.41 | 6.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.81 | 6.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.90 | 5.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.00 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $146.25 | 4.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $81.43 | 2.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.08 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,069.94 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $592.16 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $353.11 | 3 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $232.77 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $193.92 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $193.41 | 11 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $169.79 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.65 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $81.43 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $81.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.34 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 110 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 94 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
110 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 753 | 163 |
| Losartan Potassium | Losartan Potassium | 582 | 110 |
| Metformin Hcl | Metformin Hcl | 536 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 525 | 100 |
| Diclofenac Epolamine | Diclofenac Epolamine | 521 | 94 |
| Omeprazole | Omeprazole | 504 | 136 |
| Vascepa | Icosapent Ethyl | 496 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 89 |
| Alendronate Sodium | Alendronate Sodium | 325 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 44 |
| Simvastatin | Simvastatin | 239 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 231 | 54 |
| Halobetasol Propionate | Halobetasol Propionate | 227 | 92 |
| Trazodone Hcl | Trazodone Hcl | 195 | 115 |
| Finasteride | Finasteride | 191 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 188 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 175 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 78 |
| Ammonium Lactate | Ammonium Lactate | 168 | 65 |
| Meclizine Hcl | Meclizine Hcl | 161 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 45 |
| Amoxicillin | Amoxicillin | 141 | 97 |
| Meloxicam | Meloxicam | 132 | 72 |
| Gabapentin | Gabapentin | 127 | 43 |
| Donepezil Hcl | Donepezil Hcl | 122 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 53 |
| Hydrocortisone | Hydrocortisone | 117 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 38 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 114 | 40 |
| Naproxen | Naproxen | 112 | 74 |
| Creon | Lipase/Protease/Amylase | 110 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 110 | 40 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 108 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 16 |
| Farxiga | Dapagliflozin Propanediol | 94 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 55 |
| Jardiance | Empagliflozin | 83 | 15 |
| Azelastine Hcl | Azelastine Hcl | 77 | 37 |
| Azithromycin | Azithromycin | 75 | 59 |
| Ketoconazole | Ketoconazole | 67 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 24 |
| Loperamide | Loperamide Hcl | 63 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 21 |
| Ibuprofen | Ibuprofen | 60 | 45 |
| Alcohol Pads | Alcohol Antiseptic Pads | 56 | 15 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 55 | 17 |
| Glipizide Er | Glipizide | 53 | suppressed |
| Lisinopril | Lisinopril | 52 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 49 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | 12 |
| Vemlidy | Tenofovir Alafenamide | 47 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 46 | 12 |
| Gemfibrozil | Gemfibrozil | 45 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 11 |
| Acarbose | Acarbose | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 31 |
| Procto-Med Hc | Hydrocortisone | 33 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 26 |
| Eliquis | Apixaban | 29 | suppressed |
| Ciclopirox | Ciclopirox | 28 | 14 |
| Entecavir | Entecavir | 27 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 26 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 18 |
| Valsartan | Valsartan | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Tacrolimus | Tacrolimus | 21 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 14 |
| Furosemide | Furosemide | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,069.94 · 65 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, FARXIGA, GARDASIL 9, LINZESS, Livdelzi, OTEZLA, PREVNAR 20, REPATHA, REZDIFFRA, SHINGRIX, VOQUEZNA, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error